

Supporting Information for

Review

Targeting histone deacetylases for cancer therapy: Trends and challenges

Tao Liang^{a,d}, Fengli Wang^b, Reham M Elhassan^d, Yongmei Cheng^a, Xiaolei Tang^{b,c}, Wengang Chen^{a,*}, Hao Fang^{d,*}, Xuben Hou^{d,*}

^a*Department of Pharmacy, the Second Hospital Affiliated Wannan Medical College, Wuhu 241000, China*

^b*Department of Science and Education, Translational Medicine Center & Vascular Disease Research Center, the Second Hospital Affiliated Wannan Medical College, Wuhu 241000, China*

^c*Clinical Pathogens Detection Engineering Center of Wuhu, Wuhu 241000, China*

^d*Department of Medicinal Chemistry and Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China*

*Corresponding authors. Tel: +86 531 88380720.

Email addresses: haofangcn@sdu.edu.cn (Hao Fang), hxb@sdu.edu.cn (Xuben Hou), 13505532539@163.com (Wengang Chen).

Received 10 November 2022; received in revised form 19 January 2023; accepted 2 February 2023

Table S1 Drugs in combination with approved HDACi in clinical trials

HDACi	Combination Drug ^a
Vorinostat	Alisertib, Alvocidib, Anastrozole, Azacytidine, Bevacizumab, Bortezomib, Busulfan, Capecitabine, Carboplatin, Carfilzomib, Carmustine, Ceritinib, Cisplatin, Clofarabine, Cobomarsen, Curcumin, Cyclophosphamide, Cytarabine, Cyclosporine, Dasatinib, Decitabine, Dexamethasone, Disulfiram, Docetaxel, Doxil, Doxorubicin, Eltrombopag, Erlotinib, Etoposide, Everolimus, Filgrastim, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Gemtuzumab, Hydroxychloroquine, Idarubicin, Ifosfamide, Irinotecan, Ixabepilone, Isotretinoin, Lenalidomide, Letrozole, Leucovorin calcium, Liposomal Lapatinib, Maraviroc, Marizomib, Melphalan, Methotrexate, Mitoxantrone, Mycophenolate, Niacinamide, Olaparib, Oxaliplatin, Ozogamicin, Paclitaxel, Pazopanib, Pegylated, Pembrolizumab, Pemetrexed, Radiation Therapy, Prednisone, Regorafenib, Rituximab, Sirolimus, Sorafenib, Tacrolimus, Tamoxifen, Temsirolimus Ch14.18 Monoclonal Antibody, Temozolomide, Topotecan, Trastuzumab, Ustekinumab, Vinorelbine, Vincristine, Zolinza.
Romidepsin	5-azacitidine, Abraxane, Alisertib, Alvocidib, Antiretrovirals, Bortezomib, Brentuximab, Busulfan, Carfilzomib, Chidamide, Cisplatin, Copanlisib, Decitabine, Dexamethasone, Doxil, Doxorubicin, Durvalumab, Duvelisib, Etoposide, Fludarabine, Gemcitabine, Ifosfamide, Ketoconazole, Lenalidomide, Nivolumab, Oxaliplatin, Parsaclisib, Pomalidomide, Pralatrexate, Rifampin, Sintilimab, Xazomib, Tenalisib, Volasertib, Venetoclax.
Belinostat	Azacitidine, Azacytidine, Atazanavir, Bevacizumab, Bortezomib, Busulfan, Caphosol, Carfilzomib, Carboplatin, Dexamethasone, Doxorubicin, Epoetin, Erlotinib, Etoposide, Glutamine, Idarubicin, Ifosfamide, Interferon-Alfa-2b, Ipilimumab, Isotretinoin, Mesna, Nivolumab, Paclitaxel, Pevonedistat, Ribociclib, Rituximab, Romidepsin, Sirolimus, Talazoparib, Tanespimycin, Volasertib, Warfarin, Zidovudine.
Panobinostat	Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Bortezomib, Carfilzomib, Capecitabine, Carboplatin, Cisplatin, Cytarabine, Daratumumab, Daunorubicin, Decitabine, Dexamethasone, Epirubicin, Etoposide, Everolimus, Fluorouracil, Gemcitabine, Ifosfamide, Ipilimumab, Lapatinib, Lenalidomide, Letrozole, Marizomib, Melphalan, Methylprednisolone, Palifermin, Pemetrexed, Rituximab, Ruxolitinib, Sorafenib, Temozolomide, Thalidomide, Trastuzumab, Velcade.
Chidamide	Adriacin, Afatinib, Anti-PD-1 antibody+Peg-Asparaginase, Azacitidine, Camrelizumab, TCR-T cell, Carboplatin, Chiauranib, Cisplatin, Crizotinib, Cyclophosphamide, Cyclosporine A, Dasatinib, Decitabine, Dexamethasone, Doxorubicin, Envafolimab, Epirubicin, Etoposide, Exemestane, Fulvestrant, Gemcitabine, Lenalidomide, Oxaliplatin, Paclitaxel, Prednisone, Rituximab, Sintilimab, Tislelizumab, Tofacitinib, Vincristine, Vinorelbine.

^aData was obtained from www.clinicaltrials.gov.




Figure S1 (A, B) Crystal structure of BRD4884 bound to HDAC2 (PDB ID: 5IWG); (C, D) Crystal structure of HDAC8 with PCI34051 (PDB ID: 6HQY); (E, F) Crystal structure of HDAC4 complexed with compound 27 (PDB ID: 4CBY); (G, H) Crystal structure of HDAC6 with Tubastatin A (PDB ID: 6THV).